Core Viewpoint - The announcement indicates that Hualan Biological has received approval from the National Medical Products Administration for clinical trials of its recombinant Exendin-4-Fc fusion protein injection (HL08) for use in overweight or obese adults, expanding its application beyond type 2 diabetes management [1] Group 1 - Hualan Biological's HL08 has been approved for clinical trials to improve weight control in obese patients, in addition to its original indication for blood sugar control in type 2 diabetes patients [1] - The approval allows the company to officially conduct clinical research to further verify the safety and efficacy of HL08, laying the groundwork for future registration and market launch [1] - This new indication enhances the company's biopharmaceutical product pipeline and optimizes its product structure [1]

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd.'s subsidiary, Chengdu Hongji Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its KH631 eye injection for the treatment of Diabetic Macular Edema (DME) [1] Group 1 - The approved indication for KH631 is specifically for Diabetic Macular Edema (DME) [1]

Group 1 - Liyang Chip's shareholders plan to reduce their holdings by a total of up to 3.94% of the company's shares [2] - New Tian Green Energy reported a 9.32% year-on-year increase in power generation for July, totaling 84.42 million megawatt-hours [3] - Springlight Technology plans to invest up to 1 billion yuan in a new project to produce 8 million clean electrical products annually [5] Group 2 - Industrial Fulian reported a net profit of 12.113 billion yuan for the first half of the year, a year-on-year increase of 38.61% [8] - Yanjing Beer achieved a net profit of 1.103 billion yuan in the first half of the year, up 45.45% year-on-year [11] - Changqing Co. reported a net profit of 42.278 million yuan for the first half of the year, a significant increase of 117.75% [9] Group 3 - Seiyun Circuit plans to invest 125 million yuan to acquire a 3.82% stake in Shenzhen New Sound Semiconductor [6] - Crystal New Materials reported a net profit of 37.6744 million yuan for the first half of the year, a decrease of 7.3% year-on-year [7] - Kaipu Testing reported a net profit of 40.7898 million yuan for the first half of the year, a year-on-year increase of 3.73% [10]